CN101588801B - Iap抑制剂和flt3抑制剂的组合 - Google Patents

Iap抑制剂和flt3抑制剂的组合 Download PDF

Info

Publication number
CN101588801B
CN101588801B CN2007800421047A CN200780042104A CN101588801B CN 101588801 B CN101588801 B CN 101588801B CN 2007800421047 A CN2007800421047 A CN 2007800421047A CN 200780042104 A CN200780042104 A CN 200780042104A CN 101588801 B CN101588801 B CN 101588801B
Authority
CN
China
Prior art keywords
alkyl
aryl
ethyl
cyclohexyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800421047A
Other languages
English (en)
Chinese (zh)
Other versions
CN101588801A (zh
Inventor
J·D·格里芬
L·扎维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Dana Farber Cancer Institute Inc
Original Assignee
Novartis AG
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Dana Farber Cancer Institute Inc filed Critical Novartis AG
Priority claimed from PCT/US2007/085579 external-priority patent/WO2008067280A2/en
Publication of CN101588801A publication Critical patent/CN101588801A/zh
Application granted granted Critical
Publication of CN101588801B publication Critical patent/CN101588801B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800421047A 2006-11-28 2007-11-27 Iap抑制剂和flt3抑制剂的组合 Expired - Fee Related CN101588801B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US60/867,448 2006-11-28
US89108807P 2007-02-22 2007-02-22
US60/891,088 2007-02-22
PCT/US2007/085579 WO2008067280A2 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors

Publications (2)

Publication Number Publication Date
CN101588801A CN101588801A (zh) 2009-11-25
CN101588801B true CN101588801B (zh) 2011-12-28

Family

ID=41372691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800421047A Expired - Fee Related CN101588801B (zh) 2006-11-28 2007-11-27 Iap抑制剂和flt3抑制剂的组合

Country Status (3)

Country Link
CN (1) CN101588801B (es)
ES (1) ES2366299T3 (es)
ZA (1) ZA200902942B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3455221B1 (en) * 2016-05-09 2020-03-11 H. Hoffnabb-La Roche Ag Dimeric compounds
US10463029B1 (en) * 2018-06-07 2019-11-05 Regeneron Pharmaceuticals, Inc. Rodent model of steel syndrome

Also Published As

Publication number Publication date
ZA200902942B (en) 2010-09-29
CN101588801A (zh) 2009-11-25
ES2366299T3 (es) 2011-10-19

Similar Documents

Publication Publication Date Title
RU2456983C2 (ru) Комбинация ингибиторов iap и flt3
CN100384424C (zh) 协同治疗癌症的方法和组合物
CN1582150B (zh) 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
US6635666B2 (en) Cancer treatment with epothilones
AU2007234382B2 (en) Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
TWI330530B (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6302838B1 (en) Cancer treatment with epothilones
US20090054415A1 (en) Combinations, methods and compositions for treating cancer
AU2007342225A1 (en) Use of IAP inhibitors for the treatment of acute myeloid leukemia
KR20210002015A (ko) Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN100457111C (zh) 星孢素衍生物制备药物的用途
CN113476608A (zh) 一种用于治疗癌症的组合药物
CN101588801B (zh) Iap抑制剂和flt3抑制剂的组合
AU2007234379A1 (en) Combinations of therapeutic agents for treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Patentee after: Dana Farber Cancer Institute Inc.

Address before: Basel

Patentee before: Novartis AG

Patentee before: Dana Farber Cancer Institute Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111228

Termination date: 20141127

EXPY Termination of patent right or utility model